title: The use of continuous infusion of factor concentrates in the treatment of hemophilia.
abstract: Bolus infusion of clotting factor concentrates remains the most common approach to the treatment or prevention of bleeding in patients with hemophilia. Although successful use of continuous infusion of such concentrates has been reported by several groups, this alternative treatment method has not achieved widespread popularity. We report here our experience in one hemophilia center with the use of continuous infusion of factor VIII and factor IX concentrates in 13 patients, 11 with hemophilia A, and 2 with hemophilia B. All patients were treated successfully for bleeding episodes (e.g., hemarthroses, intracranial, or gastrointestinal bleeding) or for surgical procedures (appendectomy, thoracotomy, etc.). Three patients with low titer factor VIII inhibitors were treated successfully with constant infusion therapy, requiring a mean dose of factor VIII concentrate 2.3 fold (8.20 u/kg/h) higher than that of the patients without inhibitors (3.63 u/kg/h) to maintain a circulating plasma level of factor VIII of 1 u/ml. The use of constant infusion of clotting factor concentrates is safe, efficacious, and more convenient than bolus therapy of factor concentrates and should be considered for hospitalized hemophilia patients requiring replacement therapy.
authors.affiliation: Department of Medicine, University of Connecticut School of Medicine, Farmington.
authors.forename: R D
authors.initials: RD
authors.lastname: Bona
authors.forename: R A
authors.initials: RA
authors.lastname: Weinstein
authors.forename: S J
authors.initials: SJ
authors.lastname: Weisman
authors.forename: A
authors.initials: A
authors.lastname: Bartolomeo
authors.forename: F R
authors.initials: FR
authors.lastname: Rickles
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D005164:Factor IX / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D005169:Factor VIII / Q000008:administration & dosage* / Q000627:therapeutic use; D006467:Hemophilia A / Q000097:blood / Q000188:drug therapy*; D006470:Hemorrhage / Q000188:drug therapy / Q000517:prevention & control; D006487:Hemostasis; D006801:Humans; D007262:Infusions, Intravenous / Q000379:methods; D007431:Intraoperative Complications / Q000517:prevention & control; D013514:Surgical Procedures, Operative; D013927:Thrombosis / Q000139:chemically induced
chemical_list: D005169:Factor VIII; D005164:Factor IX